Literature DB >> 12383481

Diagnostic evidence for the presence of beta-agonists using two consecutive derivatization procedures and gas chromatography-mass spectrometric analysis.

Lúcia Damasceno1, Rosa Ventura, Jari Cardoso, Jordi Segura.   

Abstract

A GC-MS procedure for the detection of different beta-agonists in urine samples based on two consecutive derivatization steps is described. The derivatization procedure is based on the consecutive formation of cyclic methylboronate derivatives followed by a second derivatization step with MSTFA on the same extract, forming TMS derivatives. Injections in the GC-MS system may be carried out after each one of the derivatization steps, obtaining enough information for unambiguous identification. Limits of detection for the two derivatization steps ranged from 0.5 to 5 ng/ml. This procedure was tested with the beta-agonists bambuterol, clenbuterol, fenoterol, formoterol, salbutamol, salmeterol, alpha-hydroxy-salmeterol and terbutaline.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12383481     DOI: 10.1016/s1570-0232(02)00414-2

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  3 in total

1.  Production and characterization of a single-chain Fv antibody-alkaline phosphatase fusion protein specific for clenbuterol.

Authors:  Xixia Liu; Hong Wang; Yan Liang; Jinyi Yang; Hongbin Zhang; Hongtao Lei; Yudong Shen; Yuanming Sun
Journal:  Mol Biotechnol       Date:  2010-05       Impact factor: 2.695

2.  HPLC-electrospray mass spectrometric assay for the determination of (R,R)-fenoterol in rat plasma.

Authors:  Danuta Siluk; Hee Seung Kim; Tyler Cole; Irving W Wainer
Journal:  J Pharm Biomed Anal       Date:  2008-07-09       Impact factor: 3.935

3.  Simultaneous identification and quantification of 20 β-receptor agonists in feed using gas chromatography-tandem mass spectrometry.

Authors:  Jie Cheng; Shi Wang; Xiao-Ou Su
Journal:  PLoS One       Date:  2013-10-03       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.